In conclusion, ADx-SuperARMS is likely to provide a highly sensitive and specific noninvasive detection of EGFR mutations in clinical blood samples from advanced lung adenocarcinoma patients to guide target therapy as well as to monitor drug resistance, and the EGFR mutation status detected in plasma with ADx-SuperARMS could predict the efficacy of EGFR-TKIs treatment. Here, EGFR is linked to lung adenocarcinoma.